Molecules (Jun 2022)

Repositioning of Quinazolinedione-Based Compounds on Soluble Epoxide Hydrolase (sEH) through 3D Structure-Based Pharmacophore Model-Driven Investigation

  • Erica Gazzillo,
  • Stefania Terracciano,
  • Dafne Ruggiero,
  • Marianna Potenza,
  • Maria Giovanna Chini,
  • Gianluigi Lauro,
  • Katrin Fischer,
  • Robert Klaus Hofstetter,
  • Assunta Giordano,
  • Oliver Werz,
  • Ines Bruno,
  • Giuseppe Bifulco

DOI
https://doi.org/10.3390/molecules27123866
Journal volume & issue
Vol. 27, no. 12
p. 3866

Abstract

Read online

The development of new bioactive compounds represents one of the main purposes of the drug discovery process. Various tools can be employed to identify new drug candidates against pharmacologically relevant biological targets, and the search for new approaches and methodologies often represents a critical issue. In this context, in silico drug repositioning procedures are required even more in order to re-evaluate compounds that already showed poor biological results against a specific biological target. 3D structure-based pharmacophoric models, usually built for specific targets to accelerate the identification of new promising compounds, can be employed for drug repositioning campaigns as well. In this work, an in-house library of 190 synthesized compounds was re-evaluated using a 3D structure-based pharmacophoric model developed on soluble epoxide hydrolase (sEH). Among the analyzed compounds, a small set of quinazolinedione-based molecules, originally selected from a virtual combinatorial library and showing poor results when preliminarily investigated against heat shock protein 90 (Hsp90), was successfully repositioned against sEH, accounting the related built 3D structure-based pharmacophoric model. The promising results here obtained highlight the reliability of this computational workflow for accelerating the drug discovery/repositioning processes.

Keywords